Trial on Radical Upfront Surgery in Advanced Ovarian Cancer

Running, not enrolling · Not applicable

Conditions studied: Ovarian Cancer

In brief

This study consists of three parts, whereas Part 1 and Part 2 are performed in Germany only, and Part 3 is a multinational trial. All patients with suspicion of advanced ovarian cancer are detected in the participating study centers in a pre-screening. The study centers will register all patients with suspected ovarian cancer in a screening log. After the patients have given informed consent, they can be enrolled in different parts of the study. TRUST-Trial: This part compares two strategies in the therapy of advanced ovarian cancer. En detail, this part of the trial will evaluate if one of two strategies of timing surgery within the therapeutic procedures may show any significant advances in terms of overall survival over the other.

Key facts

Study ID

NCT02828618

Run by

AGO Study Group

People needed

797

Starts

2016-07-01

Expected to finish

2025-12-01

Last updated by the study team

2025-10-03

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• suspected or histologically confirmed, newly diagnosed invasive epithelial ovarian cancer FIGO stage IIIB-IV (IV only if resectable metastasis)
• Females aged ≥ 18 years
• Patients who have given their written informed consent
• Good performance status (ECOG 0/1)
• Good ASA score (1/2)
• Preoperative CA 125/CEA ratio ≥ 25 (if CA-125 is elevated)*
• If <25 and/or biopsy with non-serous, non-endometroid histology, esophago-gastro-duodenoscopy (EGD) and colonoscopy mandatory to exclude gastrointestinal primary cancer
• Assessment of an experienced surgeon, that based on all available information, the patient can undergo the procedure and the tumor can potentially be completely resected
• Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. This ANC cannot have been induced or supported by granulocyte colony stimulating factors.
• Platelet count ≥ 100 x 109/L.
• Renal function: Serum-Creatinine ≤ 1.5 x institutional upper limit normal (ULN).
• Hepatic function:
• Bilirubin ≤ 1.5 x ULN.
• SGOT ≤ 3 x ULN
• Alkaline phosphatase ≤ 2.5 x ULN.
• Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE Grade 1.

You may not qualify if…

• Non epithelial ovarian malignancies and borderline tumors
• Secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma FIGO IA G1/2, non melanoma skin cancer, breast cancer T1 N0 M0 G1/2) or with any signs of relapse or activity.
• Recurrent ovarian cancer
• Prior chemotherapy for ovarian cancer or abdominal/pelvic radiotherapy
• Unresectable parenchymal lung metastasis, liver metastasis or bulky lymph-nodes in the mediastinum in CT chest and abdomen/pelvis
• Clinical relevant dysfunctions of blood clotting (including drug induced)
• Any significant medical reasons, age or performance status that will not allow to perform the study procedures (estimation of investigator)
• Pregnancy
• Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent
• Any reasons interfering with regular follow-up

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Medical University of Vienna — Vienna, Austria
• University Hospital, Rigshospitalet — Copenhagen, Denmark
• Institut Bergonié — Bordeaux, France
• Hôpital Européen Georges Pompidou (HEGP) — Paris, France
• Institute Gustave Roussy — Villejuif, France
• Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie — Berlin, Germany
• Universitätsklinikum Carl Gustav Carus Dresden, Klinik & Poliklinik f. Frauenheilkunde & Geburtshilfe — Dresden, Germany
• Kaiserswerther Diakonie; Florence-Nightingale-Hospital — Düsseldorf, Germany
• Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gyn. Onkologie — Essen, Germany
• Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie — Hamburg, Germany
• Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München — München, Germany
• Klinikum rechts der Isar, Frauen- und Poliklinik — München, Germany
• Universitätsklinikum Tübingen — Tübingen, Germany
• European Institute of Oncology; Gynecologic Cancer Surgery — Milan, Italy
• Fondazione IRCCS Istituto Nazionale Tumori - Milan — Milan, Italy
• Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli — Naples, Italy
• Skane University Hospital — Lund, Sweden
• Karolinska University Hospital — Solna, Sweden
• Imperial College London, Hammersmith Hospital, Surgery&Cancer — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.